Panacur Boli 250 ad us. vet.

Hauptinformation

  • Handelsname:
  • Panacur® Boli 250 ad us. vet.
  • Darreichungsform:
  • Panacur® Boli 250 ad us. vet.
  • Verwenden für:
  • Tiere
  • Art der Medizin:
  • allopathic Droge

Dokumenten

  • Information für medizinisches Fachpersonal:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie die Packungsbeilage für medizinisches Fachpersonal.

Lokalisierung

  • Erhältlich in:
  • Panacur® Boli 250 ad us. vet.
    Schweiz
  • Sprache:
  • Deutsch

Therapeutische Informationen

  • Therapiegruppe:
  • Breitspektrum-Anthelmin­thi­kum gegen unreife und reife Stadien von Magen-Darm-Nematoden und Lungenwürmern sowie gegen Bandwürme

Weitere Informationen

Status

  • Quelle:
  • Institut für Veterinärpharmakologie
  • Zulassungsnummer:
  • 41039
  • Letzte Änderung:
  • 02-09-2017

Packungsbeilage: zusammensetzung, kinische angaben, nebenwirkungen, wechselwirkungen, dosierung, schwangerschaft, stillzeit

Panacur

Boli 250 ad us. vet.

MSD Animal Health GmbH

Breitspektrum-Anthelminthikum gegen unreife und reife Stadien von Magen-Darm-

Nematoden und Lungenwürmern sowie gegen Bandwürmer bei Schafen

ATCvet: QP52AC13

Zusammensetzung

Wirkstoff: Fenbendazolum

250 mg

-Hilfsstoffe: Excip. pro bolo

-galenische Form: Boli

Fachinformationen Wirkstoffe (CliniPharm)

Fenbendazol

Eigenschaften / Wirkungen

Der grundlegende Mechanismus der anthelminthischen Wirkung von Fenbendazol ist eine

Hemmung der Polymerisation von Tubulin zu Mikrotubuli. Dadurch werden wichtige

strukturelle Eigenschaften der Helminthenzelle beeinträchtigt, wie die Ausbildung des

Zytoskeletts, die Spindelbildung bei der Mitose sowie Aufnahme und intrazellulärer

Transport von Nährstoffen und Stoffwechselsubstraten. Als Folge kommt es zu einer

Erschöpfung der Energiereserven mit nachfolgendem Absterben des Parasiten und seiner

Expulsion nach 2 - 3 Tagen.

Fenbendazol besitzt eine ovizide Wirkung, die nach ca. 8 Stunden infolge einer Störung

der Spindelbildung und des Metabolismus während der Embryogenese eintritt.

Fenbendazol ist hochwirksam gegen adulte und immature Magen-Darm-Nematoden und

Lungenwürmer, sowie gegen inhibierte und histotrope Larvenstadien. Darüber hinaus zeigt

Fenbendazol eine gute Wirksamkeit gegen verschiedene Bandwurmarten.

Die Verabreichung von Panacur

Boli an Mutterschafe kann in jedem Stadium der

Trächtigkeit oder Laktation erfolgen.

Pharmakokinetik

Fenbendazol wird nach oraler Applikation zum Teil resorbiert und dann zu einem

erheblichen Teil in der Leber metabolisiert. Die Resorption erfolgt bei Tieren mit

einhöhligem Magen schneller als bei Wiederkäuern. Als Hauptmetaboliten werden ein

Sulfoxid und ein Sulfon-Metabolit gebildet.

Die Halbwertzeit von Fenbendazol im Serum beträgt nach oraler Applikation der

empfohlenen Dosis speziesabhängig zwischen 10 und 33 Stunden. Fenbendazol und

seine Metaboliten verteilen sich im Gesamtorganismus, wobei hohe Konzentrationen in

der Leber erreicht werden. Die Ausscheidung von unverändertem und metabolisiertem

Fenbendazol erfolgt überwiegend (> 90%) über den Kot, zu geringem Teil auch über den

Urin und die Milch.

Indikationen

Befall von Schafen mit Magen-Darm-Nematoden, Lungenwürmern und Bandwürmern wie

Haemonchus spp., Ostertagia spp., Trichostrongylus spp., Cooperia spp., Nematodirus

spp., Oesophagostomum spp., Chabertia spp., Bunostomum spp., Gaigeria pachyscelis,

Trichuris spp., Strongyloides spp., Dictyocaulus filaria, Moniezia spp.

Körper-

gewicht

(KGW)

Befall mit

Magen-Darm- und

Lungenwürmern

Befall mit

Bandwürmern

Richtdosis:

5 mg Fenbendazol

/kg KGW

Richtdosis:

10 mg Fenbendazol

/kg KGW

25 kg

½ Bolus

1 Bolus

50 kg

1 Bolus

2 Boli

75 kg

1 ½ Boli

3 Boli

Es empfiehlt sich, Panacur

Boli 250 mit einem Pilleneingeber zu verabreichen. Es ist

darauf zu achten, dass die Boli abgeschluckt werden. Diätmassnahmen vor oder nach der

Behandlung sind nicht erforderlich. Nach Neuinfektionen ist die Behandlung zu

wiederholen.

Anwendungseinschränkungen

Kontraindikationen

Keine.

Vorsichtsmassnahmen:

Keine.

Unerwünschte Wirkungen

VetVigilance: Pharmacovigilance-Meldung erstatten

Keine bekannt.

Leber:

21 Tage

Übrige essbare Gewebe:14 Tage

Milch:

6 Tage

Wechselwirkungen

Eine gleichzeitige Anwendung mit Präparaten zur Leberegelbekämpfung ist wegen der

Möglichkeit von Unverträglichkeitserscheinungen zu vermeiden.

Sonstige Hinweise

Lagerung bei Raumtemperatur (15 - 25°C).

Medikament, für Kinder unzugänglich aufbewahren.

Packungen

Schachtel mit 50 Boli

Abgabekategorie: B

Swissmedic Nr. 41'039

Informationsstand: 06/2005

Dieser Text ist behördlich genehmigt.

17-1-2019

Safety and efficacy of benzoic acid as a technological feed additive for weaned piglets and pigs for fattening

Safety and efficacy of benzoic acid as a technological feed additive for weaned piglets and pigs for fattening

Published on: Wed, 16 Jan 2019 The additive under assessment is pure benzoic acid (> 99.8%), manufactured in the form of flakes. It is intended to be used as a technological feed additive (acidity regulator) in feedingstuffs for weaned piglets and pigs for fattening, with maximum contents of 5,000 and 10,000 mg/kg complete feed, respectively. Benzoic acid is safe for weaned piglets at 5,000 mg/kg complete feed, and at 10,000 mg/kg complete feed for pigs for fattening. The use of benzoic acid in feedings...

Europe - EFSA - European Food Safety Authority EFSA Journal

10-1-2019

Safety evaluation of the food enzyme alpha‐amylase from a genetically modified Trichoderma reesei (strain DP‐Nzb48)

Safety evaluation of the food enzyme alpha‐amylase from a genetically modified Trichoderma reesei (strain DP‐Nzb48)

Published on: Wed, 09 Jan 2019 The food enzyme alpha‐amylase (4‐α‐d‐glucan glucanohydrolase; EC 3.2.1.1) is produced with a genetically modified strain of Trichoderma reesei by Danisco US Inc. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This α‐amylase is intended to be used in distilled alcohol production and brewing processes. Residual amounts of total organic solids (TOS) are removed by distill...

Europe - EFSA - European Food Safety Authority EFSA Journal

6-1-2019

Lupin Pharmaceuticals, Inc. Issues Voluntary Recall of Ceftriaxone for Injection USP, 250mg, 500mg, 1g and 2g

Lupin Pharmaceuticals, Inc. Issues Voluntary Recall of Ceftriaxone for Injection USP, 250mg, 500mg, 1g and 2g

Lupin Pharmaceuticals, Inc. is voluntarily recalling 5 lots of Ceftriaxone for Injection, USP, 250mg, 10 lots of Ceftriaxone for Injection, USP, 500mg, 24 lots of Ceftriaxone for Injection, USP, 1g and 3 lots of Ceftriaxone for Injection, USP 2g, to the hospital/physician level. The products have been found to contain visual grey particulate matter in reconstituted vials.

FDA - U.S. Food and Drug Administration

21-12-2018

Ampi-Kur ad us. vet., Eutersuspension

Ampi-Kur ad us. vet., Eutersuspension

● Die Zulassung ist am 21.12.2018 erloschen.

Institut für Veterinärpharmakologie und toxikologie

20-12-2018

Versican Plus DHPPi/L4 ad us. vet.

Versican Plus DHPPi/L4 ad us. vet.

● Änderung Text "Kurzbezeichnung", "Zusammensetzung", "Indikation", "Dosierung / Anwendung", "Anwendungseinschränkungen", "Unerwünschte Wirkungen", "Wechselwirkungen", "Sonstige Hinweise" und "Packungen"

Institut für Veterinärpharmakologie und toxikologie

20-12-2018

Versican Plus DHPPi/L4R ad us. vet.

Versican Plus DHPPi/L4R ad us. vet.

● Änderung Text "Zusammensetzung", "Indikation", "Dosierung / Anwendung", "Anwendungseinschränkungen", "Unerwünschte Wirkungen", "Wechselwirkungen", "Sonstige Hinweise" und "Packungen"

Institut für Veterinärpharmakologie und toxikologie

20-12-2018

Versican Plus L4 ad us. vet.

Versican Plus L4 ad us. vet.

● Änderung Text "Eigenschaften", "Dosierung / Anwendung", "Anwendungseinschränkungen", "Unerwünschte Wirkungen", "Wechselwirkungen" und "Sonstige Hinweise"

Institut für Veterinärpharmakologie und toxikologie

20-12-2018

Versican Plus Pi/L4 ad us. vet.

Versican Plus Pi/L4 ad us. vet.

● Änderung Text "Kurzbezeichnung", "Zusammensetzung", "Indikationen", "Dosierung / Anwendung", "Anwendungseinschränkungen", "Unerwünschte Wirkungen" und "Wechselwirkungen"

Institut für Veterinärpharmakologie und toxikologie

20-12-2018

Perlutex ad us. vet., Tabletten

Perlutex ad us. vet., Tabletten

● Änderung Text "Zusammensetzung", "Dosierung / Anwendung" und "Sonstige Hinweise"

Institut für Veterinärpharmakologie und toxikologie

15-12-2018

Schauma-Dip ad us. vet., Zitzendesinfektionsmittel

Schauma-Dip ad us. vet., Zitzendesinfektionsmittel

● Neue Zulassungsinhaberin: Halag Chemie AG

Institut für Veterinärpharmakologie und toxikologie

14-12-2018

Risk to human health related to the presence of perfluorooctane sulfonic acid and perfluorooctanoic acid in food

Risk to human health related to the presence of perfluorooctane sulfonic acid and perfluorooctanoic acid in food

Published on: Thu, 13 Dec 2018 The European Commission asked EFSA for a scientific evaluation on the risks to human health related to the presence of perfluorooctane sulfonic acid (PFOS) and perfluorooctanoic acid (PFOA) in food. Regarding PFOS and PFOA occurrence, the final data set available for dietary exposure assessment contained a total of 20,019 analytical results (PFOS n = 10,191 and PFOA n = 9,828). There were large differences between upper and lower bound exposure due to analytical methods with i...

Europe - EFSA - European Food Safety Authority Publications

14-12-2018

Bovilis BTV8 ad us. vet.

Bovilis BTV8 ad us. vet.

● Die Zulassung ist am 14.12.2018 erloschen.

Institut für Veterinärpharmakologie und toxikologie

12-12-2018

Activyl TickPlus spot-on Hund XS ad us. vet., insektizide Loesung zum Auftragen auf die Haut

Activyl TickPlus spot-on Hund XS ad us. vet., insektizide Loesung zum Auftragen auf die Haut

● Umwandlung in Exportzulassung (Exportspezialität): nur für den Vertrieb im Ausland

Institut für Veterinärpharmakologie und toxikologie

12-12-2018

Activyl TickPlus spot-on Hund S ad us. vet., insektizide Loesung zum Auftragen auf die Haut

Activyl TickPlus spot-on Hund S ad us. vet., insektizide Loesung zum Auftragen auf die Haut

● Umwandlung in Exportzulassung (Exportspezialität): nur für den Vertrieb im Ausland

Institut für Veterinärpharmakologie und toxikologie

12-12-2018

Activyl TickPlus spot-on Hund M ad us. vet., insektizide Loesung zum Auftragen auf die Haut

Activyl TickPlus spot-on Hund M ad us. vet., insektizide Loesung zum Auftragen auf die Haut

● Umwandlung in Exportzulassung (Exportspezialität): nur für den Vertrieb im Ausland

Institut für Veterinärpharmakologie und toxikologie

12-12-2018

Activyl TickPlus spot-on Hund L ad us. vet., insektiztide Loesung zum Auftragen auf die Haut

Activyl TickPlus spot-on Hund L ad us. vet., insektiztide Loesung zum Auftragen auf die Haut

● Umwandlung in Exportzulassung (Exportspezialität): nur für den Vertrieb im Ausland

Institut für Veterinärpharmakologie und toxikologie

12-12-2018

Activyl TickPlus spot-on Hund XL ad us. vet., insektizide Loesung zum Auftragen auf die Haut

Activyl TickPlus spot-on Hund XL ad us. vet., insektizide Loesung zum Auftragen auf die Haut

● Umwandlung in Exportzulassung (Exportspezialität): nur für den Vertrieb im Ausland

Institut für Veterinärpharmakologie und toxikologie

12-12-2018

Carofertin ad us. vet., Injektionsemulsion

Carofertin ad us. vet., Injektionsemulsion

● Die Neuzulassung erfolgte am 12.12.2018.

Institut für Veterinärpharmakologie und toxikologie

11-12-2018

Simparica 5 mg ad us. vet., Kautabletten fuer Hunde

Simparica 5 mg ad us. vet., Kautabletten fuer Hunde

● Indikationserweiterung (Demodex canis, Otodectes cynotis) ● Änderung Text "Eigenschaften / Wirkungen", "Indikationen", "Dosierung / Anwendung" und "Unerwünschte Wirkungen"

Institut für Veterinärpharmakologie und toxikologie

11-12-2018

Simparica 10 mg ad us. vet., Kautabletten fuer Hunde

Simparica 10 mg ad us. vet., Kautabletten fuer Hunde

● Indikationserweiterung (Demodex canis, Otodectes cynotis) ● Änderung Text "Eigenschaften / Wirkungen", "Indikationen", "Dosierung / Anwendung" und "Unerwünschte Wirkungen"

Institut für Veterinärpharmakologie und toxikologie

11-12-2018

Simparica 20 mg ad us. vet., Kautabletten fuer Hunde

Simparica 20 mg ad us. vet., Kautabletten fuer Hunde

● Indikationserweiterung (Demodex canis, Otodectes cynotis) ● Änderung Text "Eigenschaften / Wirkungen", "Indikationen", "Dosierung / Anwendung" und "Unerwünschte Wirkungen"

Institut für Veterinärpharmakologie und toxikologie

11-12-2018

Simparica 40 mg ad us. vet., Kautabletten fuer Hunde

Simparica 40 mg ad us. vet., Kautabletten fuer Hunde

● Indikationserweiterung (Demodex canis, Otodectes cynotis) ● Änderung Text "Eigenschaften / Wirkungen", "Indikationen", "Dosierung / Anwendung" und "Unerwünschte Wirkungen"

Institut für Veterinärpharmakologie und toxikologie

11-12-2018

Simparica 80 mg ad us. vet., Kautabletten fuer Hunde

Simparica 80 mg ad us. vet., Kautabletten fuer Hunde

● Indikationserweiterung (Demodex canis, Otodectes cynotis) ● Änderung Text "Eigenschaften / Wirkungen", "Indikationen", "Dosierung / Anwendung" und "Unerwünschte Wirkungen"

Institut für Veterinärpharmakologie und toxikologie

11-12-2018

Simparica 120 mg ad us. vet., Kautabletten fuer Hunde

Simparica 120 mg ad us. vet., Kautabletten fuer Hunde

● Indikationserweiterung (Demodex canis, Otodectes cynotis) ● Änderung Text "Eigenschaften / Wirkungen", "Indikationen", "Dosierung / Anwendung" und "Unerwünschte Wirkungen"

Institut für Veterinärpharmakologie und toxikologie

11-12-2018

Zulvac 8 Bovis ad us. vet., Suspension zur Injektion fuer Rinder

Zulvac 8 Bovis ad us. vet., Suspension zur Injektion fuer Rinder

● Änderung Text gesamte Arzneimittelinformation

Institut für Veterinärpharmakologie und toxikologie

7-12-2018

Magnesium citrate malate as a source of magnesium added for nutritional purposes to food supplements

Magnesium citrate malate as a source of magnesium added for nutritional purposes to food supplements

Published on: Thu, 06 Dec 2018 The present scientific opinion deals with the assessment of the bioavailability of magnesium, from the proposed nutrient source, magnesium citrate malate (MgCM), when added for nutritional purposes to food supplements. MgCM is a mixed salt consisting of magnesium cations and citrate and malate anions, and with a magnesium content of 12–15%. MgCM is proposed to be used in food supplements that are intended to provide up to 300–540 mg/day magnesium. The data provided demonst...

Europe - EFSA - European Food Safety Authority Publications

7-12-2018

Re‐evaluation of propane‐1,2‐diol esters of fatty acids (E 477) as a food additive

Re‐evaluation of propane‐1,2‐diol esters of fatty acids (E 477) as a food additive

Published on: Thu, 06 Dec 2018 The EFSA Panel on Food Additives and Flavourings (FAF) provides a scientific opinion re‐evaluating the safety of propane‐1,2‐diol esters of fatty acids (E 477) when used as a food additive. The Scientific Committee on Food (SCF) in 1978 endorsed the acceptable daily intake (ADI) of 25 mg/kg body weight (bw) per day, expressed as propane‐1,2‐diol, established by the Joint FAO/WHO Expert Committee on Food Additives (JECFA) in 1974. No adverse effects were observed in short‐t...

Europe - EFSA - European Food Safety Authority Publications

6-12-2018

Hyalovet 20 ad us. vet., Injektionsloesung

Hyalovet 20 ad us. vet., Injektionsloesung

● Zusätzliche Applikationsart: intravenöse Anwendung

Institut für Veterinärpharmakologie und toxikologie

6-12-2018

Milteforan 20 mg/ml ad us. vet., orale Loesung

Milteforan 20 mg/ml ad us. vet., orale Loesung

● Änderung Text "Dosierung / Anwendung" (Verschlusssystem) und "Unerwünschte Wirkungen"

Institut für Veterinärpharmakologie und toxikologie

6-12-2018

Ubroseal ad us. vet., intramammaere Suspension

Ubroseal ad us. vet., intramammaere Suspension

● Die Neuzulassung erfolgte am 06.12.2018.

Institut für Veterinärpharmakologie und toxikologie

4-12-2018

Arnica compositum ad us. vet., Tabletten

Arnica compositum ad us. vet., Tabletten

● Die Neuzulassung erfolgte am 04.12.2018.

Institut für Veterinärpharmakologie und toxikologie

23-11-2018

Semintra 10 mg/ml ad us. vet., orale Loesung

Semintra 10 mg/ml ad us. vet., orale Loesung

● Die Neuzulassung erfolgte am 23.11.2018.

Institut für Veterinärpharmakologie und toxikologie

23-11-2018

Duvaxyn WNV ad us. vet.

Duvaxyn WNV ad us. vet.

● Änderung Packungsgrösse: Karton mit 2 Einwegspritzen

Institut für Veterinärpharmakologie und toxikologie

23-11-2018

UpCard ad us. vet. 0,75 mg, teilbare Tabletten

UpCard ad us. vet. 0,75 mg, teilbare Tabletten

● Die Neuzulassung erfolgte am 23.11.2018.

Institut für Veterinärpharmakologie und toxikologie

23-11-2018

UpCard ad us. vet. 3 mg, teilbare Tabletten

UpCard ad us. vet. 3 mg, teilbare Tabletten

● Die Neuzulassung erfolgte am 23.11.2018.

Institut für Veterinärpharmakologie und toxikologie

23-11-2018

UpCard ad us. vet. 7,5 mg, teilbare Tabletten

UpCard ad us. vet. 7,5 mg, teilbare Tabletten

● Die Neuzulassung erfolgte am 23.11.2018.

Institut für Veterinärpharmakologie und toxikologie

21-11-2018

Implementation and verification of PBPK modelling codes of TCDD in rats and humans into Berkeley Madonna

Implementation and verification of PBPK modelling codes of TCDD in rats and humans into Berkeley Madonna

Published on: Tue, 20 Nov 2018 The goal of the current work was to implement and verify previously published rat and human PBPK modelling codes for TCDD into Berkeley Madonna. The US‐EPA has used these PBPK models in the reassessment of TCDD. A procurement contract has been set up to explore the possibilities to adequately run the models and reproduce previously published results. The implementation of the available codes in Berkeley Madonna was carried out at RIKILT‐WUR under the framework agreement wi...

Europe - EFSA - European Food Safety Authority Publications

20-12-2018

.@US_FDA provides an update on new steps to revise #Essure's post-market study to collect long-term safety information following discontinuation of its U.S. sales. Read FDA Commissioner @SGottliebFDA's statement on the new steps here:  https://go.usa.gov/

.@US_FDA provides an update on new steps to revise #Essure's post-market study to collect long-term safety information following discontinuation of its U.S. sales. Read FDA Commissioner @SGottliebFDA's statement on the new steps here: https://go.usa.gov/

. @US_FDA provides an update on new steps to revise #Essure's post-market study to collect long-term safety information following discontinuation of its U.S. sales. Read FDA Commissioner @SGottliebFDA's statement on the new steps here: https://go.usa.gov/xEaNB  #MedicalDevice

FDA - U.S. Food and Drug Administration

20-12-2018

Cefuroxim Fresenius 250 mg

Rote - Liste

19-12-2018

Join us on January 17, 2019 from 1-2:30 PM EST for a webinar to help clarify the Breakthrough Devices Program final guidance for manufacturers. Find out more about the webinar:  https://go.usa.gov/xExHX  #MedicalDevice #FDApic.twitter.com/sHElqFFODy

Join us on January 17, 2019 from 1-2:30 PM EST for a webinar to help clarify the Breakthrough Devices Program final guidance for manufacturers. Find out more about the webinar: https://go.usa.gov/xExHX  #MedicalDevice #FDApic.twitter.com/sHElqFFODy

Join us on January 17, 2019 from 1-2:30 PM EST for a webinar to help clarify the Breakthrough Devices Program final guidance for manufacturers. Find out more about the webinar: https://go.usa.gov/xExHX  #MedicalDevice #FDA pic.twitter.com/sHElqFFODy

FDA - U.S. Food and Drug Administration

19-12-2018

On Dec. 18th, the @US_FDA issued the final guidance on the Breakthrough Devices Program. The guidance outlines program policies, features, and the process for manufacturers to follow when choosing to pursue the #breakthrough designation. Read more:  https

On Dec. 18th, the @US_FDA issued the final guidance on the Breakthrough Devices Program. The guidance outlines program policies, features, and the process for manufacturers to follow when choosing to pursue the #breakthrough designation. Read more: https

On Dec. 18th, the @US_FDA issued the final guidance on the Breakthrough Devices Program. The guidance outlines program policies, features, and the process for manufacturers to follow when choosing to pursue the #breakthrough designation. Read more: https://go.usa.gov/xExHq  pic.twitter.com/fAAZAQx1H5

FDA - U.S. Food and Drug Administration

19-12-2018

On 12/12/18 GE Healthcare Recalled CareScape R860 Inspiratory Safety Guard Due to Risk of Disconnection from Breathing Circuit. @US_FDA has identified this as a Class I Recall, the most serious type recall. Read more about the recall:  https://go.usa.gov/

On 12/12/18 GE Healthcare Recalled CareScape R860 Inspiratory Safety Guard Due to Risk of Disconnection from Breathing Circuit. @US_FDA has identified this as a Class I Recall, the most serious type recall. Read more about the recall: https://go.usa.gov/

On 12/12/18 GE Healthcare Recalled CareScape R860 Inspiratory Safety Guard Due to Risk of Disconnection from Breathing Circuit. @US_FDA has identified this as a Class I Recall, the most serious type recall. Read more about the recall: https://go.usa.gov/xE383  #MedicalDevice #FDA pic.twitter.com/S2EbMdmwpe

FDA - U.S. Food and Drug Administration

19-12-2018

Ciprobay® 250 mg

Rote - Liste

18-12-2018

#DYK December is #SafeToysAndGiftsMonth. Check out @US_FDA's Consumer Update on how to keep kids safe with toys containing lasers:  https://go.usa.gov/xEx2r  #FDApic.twitter.com/57pZAmSb9r

#DYK December is #SafeToysAndGiftsMonth. Check out @US_FDA's Consumer Update on how to keep kids safe with toys containing lasers: https://go.usa.gov/xEx2r  #FDApic.twitter.com/57pZAmSb9r

#DYK December is #SafeToysAndGiftsMonth. Check out @US_FDA's Consumer Update on how to keep kids safe with toys containing lasers: https://go.usa.gov/xEx2r  #FDA pic.twitter.com/57pZAmSb9r

FDA - U.S. Food and Drug Administration

14-12-2018

GE Healthcare Recalls CareScape R860 Inspiratory Safety Guard Due to Risk of Disconnection from Breathing Circuit. @US_FDA @US has identified this as a Class I Recall, the most serious type recall. Read more about the recall here:  https://go.usa.gov/xE38

GE Healthcare Recalls CareScape R860 Inspiratory Safety Guard Due to Risk of Disconnection from Breathing Circuit. @US_FDA @US has identified this as a Class I Recall, the most serious type recall. Read more about the recall here: https://go.usa.gov/xE38

GE Healthcare Recalls CareScape R860 Inspiratory Safety Guard Due to Risk of Disconnection from Breathing Circuit. @US_FDA @US has identified this as a Class I Recall, the most serious type recall. Read more about the recall here: https://go.usa.gov/xE383  #MedicalDevice #FDA pic.twitter.com/X4IprwU8R2

FDA - U.S. Food and Drug Administration

14-12-2018

#ICYMI: @US_FDA cleared a mobile medical app to help those with #opioid use disorder stay in recovery programs. Read more about the clearance here:  https://go.usa.gov/xE3ke  #FDA #MedicalDevice

#ICYMI: @US_FDA cleared a mobile medical app to help those with #opioid use disorder stay in recovery programs. Read more about the clearance here: https://go.usa.gov/xE3ke  #FDA #MedicalDevice

#ICYMI: @US_FDA cleared a mobile medical app to help those with #opioid use disorder stay in recovery programs. Read more about the clearance here: https://go.usa.gov/xE3ke  #FDA #MedicalDevice

FDA - U.S. Food and Drug Administration

13-12-2018

Ursofalk® 250mg Kapseln

Rote - Liste

11-12-2018

Metopiron® 250 mg Weichkapseln

Rote - Liste

10-12-2018

.@US_FDA is emphasizing the importance of manual cleaning prior to disinfection or sterilization and proper servicing of duodenoscopes. Read more:  https://go.usa.gov/xPShF  #MedicalDevice #FDApic.twitter.com/HiJbgPnsPt

.@US_FDA is emphasizing the importance of manual cleaning prior to disinfection or sterilization and proper servicing of duodenoscopes. Read more: https://go.usa.gov/xPShF  #MedicalDevice #FDApic.twitter.com/HiJbgPnsPt

. @US_FDA is emphasizing the importance of manual cleaning prior to disinfection or sterilization and proper servicing of duodenoscopes. Read more: https://go.usa.gov/xPShF  #MedicalDevice #FDA pic.twitter.com/HiJbgPnsPt

FDA - U.S. Food and Drug Administration

10-12-2018

EU/3/17/1906 (PTC Therapeutics International Limited)

EU/3/17/1906 (PTC Therapeutics International Limited)

EU/3/17/1906 (Active substance: Recombinant adeno-associated viral vector serotype 5 carrying the gene for the human frataxin protein) - Transfer of orphan designation - Commission Decision (2018)8634 of Mon, 10 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/0000002509

Europe -DG Health and Food Safety

10-12-2018

EU/3/16/1786 (PTC Therapeutics International Limited)

EU/3/16/1786 (PTC Therapeutics International Limited)

EU/3/16/1786 (Active substance: Recombinant adeno-associated viral vector serotype 2 carrying the gene for the human aromatic L-amino acid decarboxylase protein) - Transfer of orphan designation - Commission Decision (2018)8630 of Mon, 10 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/0000002507

Europe -DG Health and Food Safety

10-12-2018

EU/3/16/1651 (PTC Therapeutics International Limited)

EU/3/16/1651 (PTC Therapeutics International Limited)

EU/3/16/1651 (Active substance: Recombinant adeno-associated viral vector serotype 9 carrying the gene for the human E6-AP ubiquitin protein ligase) - Transfer of orphan designation - Commission Decision (2018)8632 of Mon, 10 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/0000002508

Europe -DG Health and Food Safety

1-12-2018

.@US_FDA scientists have replicated an imaging clinical trial using computer methods, suggesting in silico trials hold promise for regulatory evaluation.  https://ja.ma/2rdAtre pic.twitter.com/XiTbPfEkcj

.@US_FDA scientists have replicated an imaging clinical trial using computer methods, suggesting in silico trials hold promise for regulatory evaluation. https://ja.ma/2rdAtre pic.twitter.com/XiTbPfEkcj

. @US_FDA scientists have replicated an imaging clinical trial using computer methods, suggesting in silico trials hold promise for regulatory evaluation. https://ja.ma/2rdAtre  pic.twitter.com/XiTbPfEkcj

FDA - U.S. Food and Drug Administration

30-11-2018

#FDA In Brief: @US_FDA takes steps to advance the safety and accuracy of  blood glucose monitors to empower patients with diabetes with reliable  tools to manage their health. Read more:  https://go.usa.gov/xPMyA   #MedicalDevice

#FDA In Brief: @US_FDA takes steps to advance the safety and accuracy of blood glucose monitors to empower patients with diabetes with reliable tools to manage their health. Read more: https://go.usa.gov/xPMyA  #MedicalDevice

#FDA In Brief: @US_FDA takes steps to advance the safety and accuracy of blood glucose monitors to empower patients with diabetes with reliable tools to manage their health. Read more: https://go.usa.gov/xPMyA  #MedicalDevice

FDA - U.S. Food and Drug Administration

30-11-2018

.@US_FDA issues class I recall, the most serious type pf recall: Synaptive Medical Recalls BrightMatter Guide with SurfaceTrace Registration Due to Software Defect. Read more about the recall:  https://go.usa.gov/xPMEn  #MedicalDevicepic.twitter.com/YU9Iq

.@US_FDA issues class I recall, the most serious type pf recall: Synaptive Medical Recalls BrightMatter Guide with SurfaceTrace Registration Due to Software Defect. Read more about the recall: https://go.usa.gov/xPMEn  #MedicalDevicepic.twitter.com/YU9Iq

. @US_FDA issues class I recall, the most serious type pf recall: Synaptive Medical Recalls BrightMatter Guide with SurfaceTrace Registration Due to Software Defect. Read more about the recall: https://go.usa.gov/xPMEn  #MedicalDevice pic.twitter.com/YU9Iq3Yw0b

FDA - U.S. Food and Drug Administration

30-11-2018

.@US_FDA issues class I recall, the most serious type pf recall: Zimmer  Biomet, Inc. Recalls Spinal Fusion & Long Bone Stimulators Due to Lack  of Adequate Validation and Controls to Ensure Product Cleanliness. Read  more about the recall:  https://go.us

.@US_FDA issues class I recall, the most serious type pf recall: Zimmer Biomet, Inc. Recalls Spinal Fusion & Long Bone Stimulators Due to Lack of Adequate Validation and Controls to Ensure Product Cleanliness. Read more about the recall: https://go.us

. @US_FDA issues class I recall, the most serious type pf recall: Zimmer Biomet, Inc. Recalls Spinal Fusion & Long Bone Stimulators Due to Lack of Adequate Validation and Controls to Ensure Product Cleanliness. Read more about the recall: https://go.usa.gov/xPMEK  #MedicalDevice pic.twitter.com/M55ddC98wW

FDA - U.S. Food and Drug Administration

30-11-2018

.@US_FDA has selected 8 novel medical devices as participants in #FDA’s Innovation Challenge to address the #OpioidEpidemic by preventing and treating opioid use disorder. #FDAInnovationChallenge

.@US_FDA has selected 8 novel medical devices as participants in #FDA’s Innovation Challenge to address the #OpioidEpidemic by preventing and treating opioid use disorder. #FDAInnovationChallenge

. @US_FDA has selected 8 novel medical devices as participants in #FDA’s Innovation Challenge to address the #OpioidEpidemic by preventing and treating opioid use disorder. #FDAInnovationChallenge

FDA - U.S. Food and Drug Administration

28-11-2018

PHEBURANE (Eurocept International BV)

PHEBURANE (Eurocept International BV)

PHEBURANE (Active substance: Sodium Phenylbutyrate) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)8043 of Wed, 28 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2500/T/20

Europe -DG Health and Food Safety

26-11-2018

#DYK November is #NationalHealthySkinMonth. Are you thinking about getting Dermal Fillers? Check out the @US_FDA's information on Dermal Fillers before you do:  https://go.usa.gov/xPHtk   #FDA #MedicalDevice

#DYK November is #NationalHealthySkinMonth. Are you thinking about getting Dermal Fillers? Check out the @US_FDA's information on Dermal Fillers before you do: https://go.usa.gov/xPHtk  #FDA #MedicalDevice

#DYK November is #NationalHealthySkinMonth. Are you thinking about getting Dermal Fillers? Check out the @US_FDA's information on Dermal Fillers before you do: https://go.usa.gov/xPHtk  #FDA #MedicalDevice

FDA - U.S. Food and Drug Administration

23-11-2018

.@US_FDA issues Class I Medical Device Recall, the most serious type of   recall: Oscor Recalls TB Temporary Bipolar Pacing Leads Due to  Connector Separation Causing Potential for Loss of Pacing. Find out  more:  https://go.usa.gov/xPHxF  #FDA #MedicalDe

.@US_FDA issues Class I Medical Device Recall, the most serious type of recall: Oscor Recalls TB Temporary Bipolar Pacing Leads Due to Connector Separation Causing Potential for Loss of Pacing. Find out more: https://go.usa.gov/xPHxF  #FDA #MedicalDe

. @US_FDA issues Class I Medical Device Recall, the most serious type of recall: Oscor Recalls TB Temporary Bipolar Pacing Leads Due to Connector Separation Causing Potential for Loss of Pacing. Find out more: https://go.usa.gov/xPHxF  #FDA #MedicalDevice pic.twitter.com/negJ6HU4x2

FDA - U.S. Food and Drug Administration